Primecap Management Co. CA Purchases 108,600 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

by · The Cerbat Gem

Primecap Management Co. CA increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 58.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 295,400 shares of the company’s stock after acquiring an additional 108,600 shares during the period. Primecap Management Co. CA owned approximately 0.24% of 10x Genomics worth $6,670,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of TXG. ARK Investment Management LLC grew its holdings in shares of 10x Genomics by 48.2% during the second quarter. ARK Investment Management LLC now owns 9,313,763 shares of the company’s stock worth $181,153,000 after purchasing an additional 3,029,951 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in 10x Genomics by 69.6% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company’s stock valued at $119,483,000 after purchasing an additional 2,521,289 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new position in 10x Genomics in the 2nd quarter worth approximately $11,612,000. Price T Rowe Associates Inc. MD increased its holdings in shares of 10x Genomics by 17.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,657,227 shares of the company’s stock worth $137,257,000 after buying an additional 553,053 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of 10x Genomics by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock worth $143,907,000 after buying an additional 230,145 shares during the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

10x Genomics Price Performance

Shares of TXG opened at $14.31 on Friday. The firm has a fifty day simple moving average of $17.57 and a two-hundred day simple moving average of $19.97. 10x Genomics, Inc. has a twelve month low of $12.95 and a twelve month high of $57.90.

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. During the same period last year, the firm earned ($0.51) earnings per share. 10x Genomics’s quarterly revenue was down 1.3% on a year-over-year basis. On average, equities research analysts predict that 10x Genomics, Inc. will post -1.4 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on TXG shares. JPMorgan Chase & Co. cut their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Stephens reiterated an “overweight” rating and issued a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. UBS Group decreased their price objective on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Leerink Partners started coverage on 10x Genomics in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Leerink Partnrs upgraded shares of 10x Genomics to a “strong-buy” rating in a research report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of “Moderate Buy” and an average target price of $29.19.

View Our Latest Stock Report on 10x Genomics

About 10x Genomics

(Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Articles

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG – Free Report).